Search Results - target

15 Results

Sort By:

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer

Therapeutic targets to treat Androgen Receptor Deficient and Low Prostate Cancers Methods to treat Androgen Receptor Deficient and Low Prostate Cancers by targeting 4EBP1 Prostate cancer is the second most common male cancer, affecting cells of the prostate glands. About 90% of these early stage prostate cancers are dependent on androgens for...

Published: 8/28/2024 | Updated: 8/28/2024 | Inventor(s): Andrew Hsieh

Keywords(s): Target

Category(s): Therapeutic

Targeted delivery into CD90+ cells

Selection and Use of Hematopoietic Stem Cells for Cell Transplantation and Gene Therapy Approaches Defined population predicts and quantitatively correlates with <em>in vivo</em> engraftment and multilineage potential. Hematopoietic stem cells (HSC) are the preferred target population for <em>ex vivo</em> gene therapy...

Published: 8/28/2024 | Updated: 8/28/2024 | Inventor(s): Stefan Radtke, HanS-Peter Kiem, Kurt Berckmueller, Roland Strong, Peter Rupert

Keywords(s): HSC Therapy, Lentiviral, Small Molecule, Target, Vectors

Category(s): Research Tool, Gene Therapy

TARGETING PRAC1 IN CASTRATION RESISTANT PROSTATE CANCER

Therapeutic peptide and biomarkers for castration-resistant prostate cancer (CRPC) Synthetic peptide targeting PRAC1 has been developed for the treatment of CRPC. Prostate cancer is an androgen dependent tumor, and the androgen receptor (AR) drives numerous mechanisms involved in disease progression. The standard therapy for metastatic...

Published: 5/15/2025 | Updated: 7/5/2024 | Inventor(s): Michael Haffner, Jin-Yih Low, Elizabeth Wasmuth, Chitvan Mittal

Keywords(s): Biomarker, Protein / Peptide, Target

Category(s): Diagnostic, Therapeutic

Method of adoptive T cell therapy utilizing notch signaling to enhance efficacy

Notch Activation to Improve Persistence and Efficacy of T Cell Therapies Method of using Notch ligands during culturing to improve the persistence and efficacy of CAR T cell therapies. While CAR T-based cell therapies are promising, the persistence, proliferation, and efficacy of those engineered T cell therapies need to be improved. Additionally,...

Published: 10/14/2024 | Updated: 3/10/2024 | Inventor(s): Irwin Bernstein, Stanley Riddell, Margot Pont

Keywords(s): Immuno Oncology, Target

Category(s): Therapeutic

Development of Fully Human Anti-Human Siglec-8 Antibodies as Basis for Therapeutics to Treat Eosinophilic and Mast Cell Disorders

Novel biologics targeting Siglec-8 to treat eosinophil-driven diseases Fully human mAbs, bispecific antibodies, and NK CARs that target Siglec-8. Siglec-8 is a transmembrane protein expressed on mature eosinophils, mast cells, and (to a lesser degree) basophils. Excessive eosinophil and mast cell activity have been implicated in the pathology...

Published: 2/12/2025 | Updated: 7/18/2023 | Inventor(s): Roland Walter, George Laszlo

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

Candidate T cell epitopes of short H2A histone variants (novel cancer testis antigens)

Novel Cancer/Testis Antigen: T Cell Epitopes of Short H2A Histone Variants Short H2A histone variant epitopes commonly expressed in Diffuse Large B Cell Lymphoma to be used as immunotherapy targets By analyzing data from patients with a variety of cancers, Dr. Jay Sarthy’s group at Fred Hutch Cancer Center have identified short H2A histone...

Published: 2/4/2025 | Updated: 1/25/2023 | Inventor(s): Jay Sarthy, Antoine Molaro, Marie Bleakley, Guo-Liang Chew

Keywords(s): Target

Category(s): Therapeutic

Mesothelin directed chimeric antigen receptor T cells for treatment of acute myeloid leukemia

Mesothelin-directed CAR T Cells for the Treatment of Acute Myeloid Leukemia CAR T cells targeting mesothelin to treat Leukemia Despite maximally intensive therapy, approximately 40% of patients with acute myeloid leukemia (AML) will relapse. An effective targeted therapy is still needed to save the lives of AML patients. Through computational...

Published: 10/14/2024 | Updated: 1/20/2023 | Inventor(s): Soheil Meshinchi, Quy Le, Rhonda Ries

Keywords(s): Biomarker, Target, Vectors

Category(s): Cell Therapy

High Affinity MAGE-A1 T-cell Receptors

TCR Cell Therapy Targeting MAGE-A1 High-affinity MAGE-A1-specific TCR for the treatment of multiple myeloma and solid tumors. The MAGE family are CTAs expressed in many tumor types and MAGE-A1 has been shown to directly drive tumorigenesis. Specifically, MAGE-A1 is expressed in about 50% of multiple myeloma, up to 60% in triple negative...

Published: 5/15/2025 | Updated: 1/19/2023 | Inventor(s): Aude Chapuis, Thomas Schmitt, Megan McAfee

Keywords(s): Immuno Oncology, Target

Category(s): Cell Therapy, Therapeutic

Chimeric and Humanized Anti-CD45 Antibody for Therapeutic Applications

Chimeric and Humanized Anti-CD45 Antibody for Therapeutic Applications Humanized antibody offers reduced toxicity and anti-mouse antibody immunization CD45 is a transmembrane cell surface glycoprotein expressed on almost all hematopoietic cells and absent on non-hematopoietic cells. CD45 is an abundantly expressed target in most hematologic...

Published: 12/6/2023 | Updated: 6/9/2022 | Inventor(s): Roland Walter, Brenda Sandmaier, David King, George Laszlo

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

Microlumenal targeting of cancer cells

Novel Method Targeting the Tumor Microenvironment as Therapeutic Treatments for Metastatic Cancers Disruption of microlumen to slow tumor growth, reduce metastasis, and increases treatment efficacy. Solid tumors and tumor cell clusters form intercellular cavities called Microlumen. These microlumen are enclosed pockets between two or...

Published: 2/4/2025 | Updated: 9/21/2020 | Inventor(s): Kevin Cheung, Emma Wrenn

Keywords(s): Biomarker, Target

Category(s): Therapeutic

1 2